Tourmaline Bio (TRML) said Tuesday its Tranquility phase 2 trial assessing monthly and quarterly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein, or hs-CRP, showed "rapid, deep and durable" reductions in hs-CRP levels through day 90.

Tranquility is a multicenter, randomized, double-blind, placebo-controlled phase 2 trial in patients with elevated hs-CRP, a biomarker associated with elevated cardiovascular risk and chronic kidney disease, and CKD stage 3 or 4. A total of 143 participants were enrolled in the trial, and 126 participants comprised the primary analysis population.

The company said the trial is the starting point of the clinical development program for pacibekitug, an anti-IL-6 monoclonal antibody developed by the company, to treat atherosclerotic cardiovascular disease and other cardiovascular diseases.

The trial results support the progress of pacibekitug into a planned phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease and support pacibekitug's advancement into a planned phase 2 proof-of-concept trial in abdominal aortic aneurysm, the company said.

Shares of the company were down more than 11% in recent Tuesday trading.

Price: 13.74, Change: -2.89, Percent Change: -17.38